Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol.
Saved in:
| Title: | Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol. |
|---|---|
| Authors: | Solanich X; Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Antolí A; Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Padullés N; Department of Pharmacy, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Fanlo-Maresma M; Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Iriarte A; Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Mitjavila F; Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Capdevila O; Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Molina M; Department of Respiratory Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Sabater J; Department of Intensive Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Bas J; Department of Immunology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Mensa-Vilaró A; Immunology Service, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Niubó J; Department of Microbiology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Calvo N; Department of Diagnostic Imaging, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Bolivar S; Department of Diagnostic Imaging, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Rigo-Bonnin R; Department of Clinical Laboratory, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain., Arregui L; Department of BUH-ICO-IDIBELL Biobank, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Tebé C; Department of Statistics, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Hereu P; Department of Clinical Pharmacology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.; Department of Clinical Research and Clinical Trial Unit (UICEC-IDIBELL), Plataforma SCRen, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Videla S; Department of Clinical Pharmacology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.; Department of Clinical Research and Clinical Trial Unit (UICEC-IDIBELL), Plataforma SCRen, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Corbella X; Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.; Evaluation of Health Determinants and Health Policies Group, Hestia Chair in Integrated Health and Social Care, School of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain. |
| Source: | Contemporary clinical trials communications [Contemp Clin Trials Commun] 2021 Mar; Vol. 21, pp. 100716. Date of Electronic Publication: 2021 Jan 19. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101671157 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2451-8654 (Electronic) Linking ISSN: 24518654 NLM ISO Abbreviation: Contemp Clin Trials Commun Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 33495742 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Solanich+X%22">Solanich X</searchLink>; Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Antolí+A%22">Antolí A</searchLink>; Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Padullés+N%22">Padullés N</searchLink>; Department of Pharmacy, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Fanlo-Maresma+M%22">Fanlo-Maresma M</searchLink>; Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Iriarte+A%22">Iriarte A</searchLink>; Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Mitjavila+F%22">Mitjavila F</searchLink>; Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Capdevila+O%22">Capdevila O</searchLink>; Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Molina+M%22">Molina M</searchLink>; Department of Respiratory Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Sabater+J%22">Sabater J</searchLink>; Department of Intensive Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Bas+J%22">Bas J</searchLink>; Department of Immunology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Mensa-Vilaró+A%22">Mensa-Vilaró A</searchLink>; Immunology Service, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Niubó+J%22">Niubó J</searchLink>; Department of Microbiology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Calvo+N%22">Calvo N</searchLink>; Department of Diagnostic Imaging, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Bolivar+S%22">Bolivar S</searchLink>; Department of Diagnostic Imaging, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Rigo-Bonnin+R%22">Rigo-Bonnin R</searchLink>; Department of Clinical Laboratory, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Arregui+L%22">Arregui L</searchLink>; Department of BUH-ICO-IDIBELL Biobank, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Tebé+C%22">Tebé C</searchLink>; Department of Statistics, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Hereu+P%22">Hereu P</searchLink>; Department of Clinical Pharmacology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.; Department of Clinical Research and Clinical Trial Unit (UICEC-IDIBELL), Plataforma SCRen, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Videla+S%22">Videla S</searchLink>; Department of Clinical Pharmacology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.; Department of Clinical Research and Clinical Trial Unit (UICEC-IDIBELL), Plataforma SCRen, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Corbella+X%22">Corbella X</searchLink>; Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.; Evaluation of Health Determinants and Health Policies Group, Hestia Chair in Integrated Health and Social Care, School of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101671157%22">Contemporary clinical trials communications</searchLink> [Contemp Clin Trials Commun] 2021 Mar; Vol. 21, pp. 100716. <i>Date of Electronic Publication: </i>2021 Jan 19. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Review – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+B%2EV%22">Elsevier B.V </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>101671157 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2451-8654 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224518654%22">24518654 </searchLink><i>NLM ISO Abbreviation: </i>Contemp Clin Trials Commun <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33495742 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.conctc.2021.100716 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 100716 Titles: – TitleFull: Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Solanich X – PersonEntity: Name: NameFull: Antolí A – PersonEntity: Name: NameFull: Padullés N – PersonEntity: Name: NameFull: Fanlo-Maresma M – PersonEntity: Name: NameFull: Iriarte A – PersonEntity: Name: NameFull: Mitjavila F – PersonEntity: Name: NameFull: Capdevila O – PersonEntity: Name: NameFull: Molina M – PersonEntity: Name: NameFull: Sabater J – PersonEntity: Name: NameFull: Bas J – PersonEntity: Name: NameFull: Mensa-Vilaró A – PersonEntity: Name: NameFull: Niubó J – PersonEntity: Name: NameFull: Calvo N – PersonEntity: Name: NameFull: Bolivar S – PersonEntity: Name: NameFull: Rigo-Bonnin R – PersonEntity: Name: NameFull: Arregui L – PersonEntity: Name: NameFull: Tebé C – PersonEntity: Name: NameFull: Hereu P – PersonEntity: Name: NameFull: Videla S – PersonEntity: Name: NameFull: Corbella X IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: 2021 Mar Type: published Y: 2021 Identifiers: – Type: issn-electronic Value: 2451-8654 Numbering: – Type: volume Value: 21 Titles: – TitleFull: Contemporary clinical trials communications Type: main |
| ResultId | 1 |
